Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on SRPT stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Joseph Schwartz’s rating is based on a combination of factors, including Sarepta Therapeutics’ proactive measures to address safety concerns related to their Elevidys program. Despite recent setbacks, such as reported cases of acute liver failure in non-ambulatory patients, the company is taking steps to mitigate these risks by pausing shipments and enhancing their immunosuppressive regimen.
Schwartz acknowledges the challenges faced by the Elevidys program, including increased regulatory scrutiny and reputational impacts. However, he believes that the risk/benefit profile of Elevidys remains favorable for younger patients with Duchenne muscular dystrophy, given the lack of alternative disease-modifying treatments. This perspective, combined with the company’s efforts to address safety issues, underpins his Buy rating for Sarepta Therapeutics’ stock.
Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, uniQure, and KalVista Pharmaceuticals. According to TipRanks, Schwartz has an average return of 11.5% and a 43.26% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $62.00 price target.